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Abstract 
The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is abundantly expressed in 
trained muscles and regulates muscle adaptation to endurance exercise. Inversely, mice lacking a 
functional PGC-1α allele in muscle exhibit reduced muscle functionality and increased inflammation. 
In isolated muscle cells, PGC-1α and the related PGC-1β counteract the induction of inflammation by 
reducing the activity of the nuclear factor κB (NFκB). We now tested the effects of these metabolic 
regulators on inflammatory reactions in muscle tissue of control and muscle-specific PGC-1α/-1β 
transgenic mice in vivo in the basal state as well as after an acute inflammatory insult. Surprisingly, we 
observed a PGC-1-dependent alteration of the cytokine profile characterized by an increase in anti-
inflammatory factors and a strong suppression of the pro-inflammatory interleukin 12 (IL-12).In 
conclusion, the anti-inflammatory environment in muscle that is promoted by the PGC-1s might 
contribute to the beneficial effects of these coactivators on muscle function and provides a molecular 
link underlying the tight mutual regulation of metabolism and inflammation. 
 
 
Highlights:  
-Muscle PGC-1s are insufficient to prevent acute systemic inflammation 
-The muscle PGC-1s however promote a local anti-inflammatory environment 
-This anti-inflammatory environment could contribute to the therapeutic effect of the PGC-1s 
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Abbreviations: IL, interleukin; LPS, lipopolysaccharide; MCKα/β, muscle-specific PGC-1α/β 
transgenic mice; NFκB, nuclear factor κB; PGC-1, peroxisome proliferator-activated receptor γ 
coactivator 1; TA, tibialis anterior; TNFα, tumor necrosis factor α; WT, wildtype 
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Introduction 
Metabolic and immune pathways intersect at multiple levels in the human body, both in the 
healthy but maybe even more importantly in the diseased state often with detrimental consequences. 
For example, a metabolic imbalance in obesity not only leads to metabolic dysregulation, but also a 
chronic systemic inflammation [1,2,3]. The latter event often originates from fat tissue with 
pronounced accumulation of pro-inflammatory macrophages (also referred to as classically activated 
or M1 macrophages) [4]. These macrophages release large quantities of pro-inflammatory cytokines, 
e.g. tumor necrosis factor α (TNFα), interleukin 6 (IL-6), and monocyte chemotactic protein 1 (MCP-
1), that further foster inflammation [5,6]. In contrast, adipose tissue of lean animals and humans 
harbors mainly alternatively activated (or M2) macrophages that express a distinct set of anti-
inflammatory cytokines, e.g. C-C motif chemokine 1 (CCL1), CCL22, IL-1 receptor antagonist (IL-
1Ra), transforming growth factor β (TGFβ), and IL-10 [5]. While M1 macrophages drive 
inflammation and are thus physiologically important during the innate immune response against 
pathogens, M2 macrophages constrain and modulate inflammatory reactions in the resolution of 
inflammation, tissue remodeling and repair. 
The aberrant activation of M1 macrophages in obesity is not only seen in adipose tissue but 
also – in other peripheral organs such as liver or skeletal muscle. Obesity promotes the build-up of 
intramuscular adipose depots and, analogous to fat tissue, M1-type macrophage accumulation [4]. This 
chronic low grade inflammation contributes to the development of insulin resistance, a hallmark of 
diabetes. . Similar to diet-induced weight loss, regular exercise also counteracts type 2 diabetes and 
limits systemic inflammation [7,8]. An important factor mediating many of the beneficial effects of 
exercise is the PPARγ coactivator 1α (PGC-1α) [9,10]. PGC-1α and the related PGC-1β coactivate an 
array of nuclear receptors and transcription factors in skeletal muscle to induce the transcription of 
genes involved in mitochondrial biogenesis and oxidative phosphorylation and thereby enable a higher 
endurance capacity [11,12]. Mice with skeletal muscle-specific overexpression of PGC-1α  (MCKα 
mice) consequently score better in running tests and have a larger proportion of slow-twitch type I and 
IIa fibers than wild-type (WT) littermates [13,14]. Mice with transgenic overexpression of PGC-1β 
(MCKβ mice) also exhibit lower fatigability but unlike the MCK mice, a switch towards IIx fibers 
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[15]. Inversely, skeletal muscle-specific deletion of PGC-1α [16] or of PGC-1β [17] results in poorer 
running performance. 
In contrast to the elevated levels of PGC-1α in endurance athletes, the expression of PGC-1α 
and PGC-1β is reduced in skeletal muscle of human diabetic patients with a coordinate depression of 
mitochondrial oxidative phosphorylation, at least in certain populations [18,19]. Importantly, in these 
patients, PGC-1α levels inversely correlate with the pro-inflammatory cytokines IL-6 and TNFα 
independent of body mass index (BMI) [20]. This suggests a mutual negative relationship between 
PGC-1 coactivators and inflammation in skeletal muscle.  
Further experimental evidence for such a link derives from mice with skeletal muscle-specific 
PGC-1α deletion that exhibit elevated levels of muscle and systemic inflammation [20]. Accordingly, 
PGC-1α and PGC-1β overexpression constrains pro-inflammatory cytokine expression upon TNFα 
exposure by inhibiting the transcriptional activity of nuclear factor κB (NF-κB) in muscle cells in vitro 
[21]. Inversely, classical NF-κB activation in muscle cells dampens the expression of proteins 
involved in oxidative phosphorylation, including PGC-1α and PGC-1β [22]. Thus, an inverse 
regulation between the PGC-1 coactivators and pro-inflammatory gene expression exists in muscle 
cells. In the present study, we expanded the in vitro findings and now explored this mutual negative 
relationship in vivo. Specifically, we defined the role of PGC-1α and PGC-1β overexpression in 
skeletal muscle on local and systemic inflammatory events triggered by injection of the inflammatory 
agents lipopolysaccharide (LPS) and TNFα. Thereby, the previously reported muscle cell autonomous 
effects of the PGC-1 coactivators in cell culture models can be separated from the consequences of 
muscle fiber-specific elevation of PGC-1α and PGC-1β on different cell types, including immune cells 
in muscle tissue in vivo. Intriguingly, we observed that elevation of the PGC-1 coactivators promotes 
an anti-inflammatory environment in muscle. 
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Material and Methods 
Mice and treatments: C57BL/6 mice expressing PGC-1α (MCKα) [14] and FVB/N mice expressing 
PGC-1β (MCKβ) [15] under the control of the muscle creatine kinase (MCK) promoter were bred with 
respective WT mice to obtain WT and transgenic littermates. Male mice were maintained on a 
standard rodent chow with 12h light/dark cycle and subjected to experiments at 8 – 12 weeks of age. 
Injections were performed under sevoflurane anesthesia. Mice were randomly assigned to one 
experimental group and subsequently injected intramuscularly (i.m.) into the TA with either PBS 
(30µl/TA), or LPS (2µg/TA) or TNFα (50ng/TA) in both legs. 4h post injection, mice were euthanized 
and blood as well as TAs collected for further analysis. All animal experiments were approved by the 
institutional and federal authorities. 
 
ELISA: To determine serum cytokine concentrations, sandwich immunoassays for TNFα and IL-6 
were performed according to the manufacturer’s instructions (Quantikine, R&D Systems). 
 
Semiquantitative real-time PCR: Muscle tissue was homogenized using matrix particles (Qbiogene) 
in a FastPrep FP120 cell disrupter (Thermo Scientific) and RNA isolated with Trizol (Invitrogen) 
while residual DNA contamination was removed by DNase I (Invitrogen) digestion. 1µg of RNA was 
reverse transcribed with SuperScript II (Invitrogen) and the resulting cDNA used as template for RT-
PCR. To detect relative expression levels, cDNA was amplified with the SYBR Green Master mix 
(Applied Biosystems) and analyzed on a StepOnePlus RT-PCR System (Applied Biosystems). The 
respective primer pairs are listed in Supplemental Table 1. All values are normalized to the expression 
of TATA-Box binding protein (TBP) and expressed as fold induction over untreated WT animals. 
 
Histology: TA muscles were snap frozen in liquid nitrogen-chilled isopentane and cut into cross 
sections on a microtome/cryostat (Leica CM1950). Specimen were stained with Mayer’s hematoxylin 
and eosin (H&E, Sigma) and light microscopically analyzed. 
 
Statistical analysis: Data were analyzed with Student’s t test using P<0.05 as significance threshold.
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Results 
Muscle PGC-1α and PGC-1β do not suppress systemic pro-inflammatory factors after LPS/TNFα 
injection in vivo 
To delineate the role of skeletal muscle PGC-1 in an acute inflammatory insult in vivo, we 
injected bacterial LPS, TNFα or PBS as vehicle control i.m. into the tibialis anterior (TA) muscle of 
wildtype (WT) control, PGC-1α (MCKα) and PGC-1β (MCKβ) muscle-specific transgenic animals. 
Importantly, separate WT control cohorts were used to reflect the difference in the mouse strain 
background (C57BL/6 for MCKα, FVB/N for MCKβ). After 4 hours, the animals were sacrificed, 
blood collected and the TA muscle isolated. First, plasma levels of the pro-inflammatory cytokines 
TNFα and IL-6 were measured. Both cytokines were not detectable in WT and MCKα mice after PBS 
injection but were strongly induced by LPS (Fig. 1A). TNFα i.m. injection moderately elevated 
systemic TNFα levels (Fig. 1A). PGC-1α expression in skeletal muscle did not have any effect on 
these cytokine levels (Fig. 1A). Similarly, the induction of systemic TNFα and IL-6 was not affected 
by transgenic overexpression of PGC-1β even though PBS injected MCKβ mice had significantly 
lower plasma TNFα levels than WT controls (Fig. 1B). Therefore, PGC-1 coactivators in vivo were not 
able to suppress LPS- or TNFα-mediated systemic induction of pro-inflammatory M1 cytokines. 
 
Muscle PGC-1α and PGC-1β do not suppress acute inflammation, but reduce the expression of the M1 
cytokine IL-12 
Even though muscle-specific overexpression of PGC-1α or PGC-1β did not affect circulating 
pro-inflammatory cytokine levels, the PGC-1s may have a local effect on inflammation in muscle. To 
test this, gene expression changes were determined in the injected TA muscles. First, PGC-1α 
expression in MCKα mice was not affected by any of the injections and accordingly remained about 6 
fold above WT levels (Fig. 2A). PGC-1β levels were not changed in PBS-injected muscles of the 
PGC-1α muscle transgenics, but were reduced in LPS-treated mice (Fig. 2A). LPS injection also 
lowered PGC-1β expression in the MCKβ model, although PGC-1β levels remained considerably 
higher compared to WT controls (about 9 fold, Fig. 2B). In all conditions, PGC-1α levels in the 
MCKβ animals were reduced to about a third of WT levels (Fig. 2B). 
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We next mapped the expression of pro-inflammatory cytokines in the TA under these 
conditions. The cytokines TNFα, IL-6, MIP-1α and MCP-1 were strongly induced in WT muscles 
after injection of inflammatory agents (Figs. 2C, D). Skeletal muscle-specific overexpression of 
neither PGC-1α nor PGC-1β affected the elevation of these pro-inflammatory cytokines in stimulated 
muscle (Figs. 2C, D). Intriguingly, muscle-specific overexpression of PGC-1α and PGC-1β 
dramatically reduced the expression of the pro-inflammatory IL-12 regardless of the respective 
stimulation (Figs. 2C, D). These findings imply that muscle-specific overexpression of PGC-1α or 
PGC-1β is insufficient to prevent local and systemic inflammation upon a strong ectopic, acute 
stimulus. 
The local inflammation induced by LPS and TNFα injections is also evident in TA cross 
sections stained with H&E. LPS and TNFα both evoked a substantial influx of immune cells compared 
to PBS-injected muscles (Figs. 2E, F). The difference in non-muscle mononuclear cells is already 
observed under basal conditions between transgenic and WT animals and persisted after injection of 
inflammatory agents, but neither PGC-1α nor PGC-1β had an inhibitory impact on that influx (Figs. 
2E, F). Interestingly, the high number of regenerating fibers with centrally located nuclei in some 
areas of the TA in the MCKβ model indicated a basal, low level of continuous fiber damage and 
regeneration in these animals that is not observed in MCKα mice. In summary, we could not confirm 
an influence of PGC-1α or PGC-1β on several pro-inflammatory cytokine expression levels and 
immune cell infiltration in muscle in vivo. However, expression of the pro-inflammatory cytokine IL-
12 was potently suppressed in PGC-1α and PGC-1β overexpressing muscles. 
 
Muscle PGC-1α and PGC-1β induce local anti-inflammatory M2 cytokines in the TA after LPS/TNFα 
injection  
IL-12 expression is closely linked to M1 macrophages and absence of IL-12 promotes an anti-
inflammatory environment favoring M2-type activation [23,24]. Therefore, the gene expression of 
anti-inflammatory cytokines was determined to obtain a comprehensive picture of the inflammatory 
environment created by the PGC-1 coactivators in skeletal muscle. Since IL-12 levels were strongly 
suppressed in the basal condition as well as after injections of inflammatory agents, the inflammatory 
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environment may already differ between genotypes in PBS injected muscles. Indeed, in control 
muscles of MCKα mice, TGFβ expression was elevated compared to WT, whereas in MCKβ mice, all 
tested M2 cytokines were higher compared to WT animals (Fig. 3). 
In WT mice, CCL1, CCL22, IL-1Ra and TGFβ were all significantly augmented by LPS and 
TNFα while IL-10 was only induced by LPS and not by TNFα (Fig. 3). PGC-1α did not alter the levels 
of CCL22, IL-1Ra and IL-10, but it clearly enhanced the expression of CCL1 after LPS and TNFα 
injection compared to WT muscles (Fig. 3A). Notably, TGFβ expression was elevated in MCKα mice 
across all experimental conditions (Fig. 3A). The higher levels of most of the tested M2 cytokines in 
PBS-injected MCKβ animals were further elevated after LPS injection except for TGFβ. TNFα did not 
elicit such clear differences between genotypes and only CCL1 expression was significantly increased 
in MCKβ muscles compared to WT (Fig. 3B). These results indicate that the PGC-1s alter the cytokine 
environment in control muscle as well as after inflammatory stimulation by differentially boosting the 
expression of anti-inflammatory markers. 
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Discussion 
Metabolism and inflammation are two biological processes that are tightly linked. We now 
report that PGC-1α and PGC-1β constitute a molecular link between metabolism and inflammation in 
skeletal muscle. Strikingly, these two PGC-1 coactivators alter the inflammatory environment with a 
corresponding muscle cytokine expression profile. In particular, anti-inflammatory factors such as 
CCL1, CCL22, IL-1Ra, TGFβ or IL-10 were elevated in one or both muscle-specific overexpression 
models depending on the experimental context, thereby creating an anti-inflammatory environment. 
Inversely, the pro-inflammatory cytokine IL-12 was strongly suppressed in both models. Studies of 
mice with an IL-12 deletion revealed deficits in M1-type cytokines and more importantly, a bias in 
macrophage activation towards M2 [23,24], suggesting that defective IL-12 production causes an 
altered macrophage polarization. 
Systemically, we did not find a difference between the inflammation in PGC-1 transgenic and 
WT animals as plasma levels of TNFα and IL-6 were comparable after the acute insults. The PGC-1s 
in skeletal muscle are therefore not able to suppress an acute inflammatory reaction of the immune 
system on whole-body level. A previous study using the same MCKα animals that were injected i.p. 
with LPS yielded similar results: plasma IL-6 and TNFα levels were not different between genotypes 
after LPS injection even though there was a reduction in basal TNFα levels [25]. This is reminiscent of 
the situation in our MCKβ model. However, it remains to be determined if PGC-1α and PGC-1β in 
skeletal muscle are beneficial in conditions of chronic systemic inflammation, e.g. obesity-related 
morbidities, where cytokine levels are only slightly but permanently elevated as opposed to the acute, 
strong but transient inflammatory response in the study by Olesen and colleagues as well as ours. 
Importantly, in contrast to the inhibited induction of IL-6, TNFα and MIP-1α by PGC-1α and 
PGC-1β in C2C12 myotubes, we did not detect a strong repression of pro-inflammatory cytokines 
after the inflammatory challenge in vivo [21]. This seeming discrepancy might reflect the absence of 
immune cells in cultures of isolated myotubes that allows the assessment of muscle cell-autonomous 
effects. In vivo, immune and other non-muscle cell types that reside within the TA most likely 
contribute much more to the overall amounts of cytokines since these cells express significantly higher 
levels of cytokines compared to muscle fibers. We therefore speculate that even though the muscle 
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cells of transgenic animals might release lower quantities of pro-inflammatory cytokines (as observed 
in vitro), this effect is outweighed by the phenotype of resident immune cells in the muscle.  
Curiously, signs of fiber damage and inflammation were detected even in sedentary MCKβ 
mice. It is thus conceivable that the supraphysiological expression of the PGC-1β transgene in these 
animals confers some detrimental effects on muscle fibers, similar to the pathological changes 
described in higher-expressing muscle-specific PGC-1α transgenic lines [14,26]. In contrast, no signs 
of fiber damage and inflammation were detected in the MCKα mice. Importantly, despite these 
potentially confounding effects of increased inflammation intrinsic to the animal models, PGC-1α and 
PGC-1β are still able to promote an anti-inflammatory cytokine environment in skeletal muscle. 
In the respective animal models, PGC-1α and PGC-1β improve the pathology of Duchenne 
muscular dystrophy and other muscle wasting diseases [27,28]. Injured and dystrophic muscles also 
depend on macrophage activity to undergo repair. Following a first phase in which necrotic muscle 
fibers are removed by M1 cells, M2 macrophages control the second phase of regeneration [29,30]. 
Given the beneficial effect of physiological PGC-1α and PGC-1β overexpression in Duchenne 
muscular dystrophy and their ability to induce an anti-inflammatory environment after an 
inflammatory insult, it is tempting to speculate that PGC-1α and PGC-1β are instrumental in muscle 
regenerative processes by modulating immune responses that are vital for proper recovery.  
In conclusion, an anti-inflammatory role of the metabolic regulators PGC-1α and PGC-1β was 
confirmed based on an altered cytokine environment in skeletal muscle tissue of transgenic animals in 
vivo. Due to crosstalk between muscle and immune cells, the greater anti-inflammatory and 
immunomodulatory context compared to WT control animals may be explained by skewed balance of 
macrophages after an inflammatory insult from M1 to M2 cells. Potential mediators of this effect 
include the secreted phosphoprotein 1 (SPP1), a protein that is regulated by PGC-1α in muscle to 
coordinate immune and endothelial cell activation for angiogenesis [31]. Likewise, meteorin-like 
(Metrnl) is a PGC-1α-controlled myokine with immunomodulatory effects [32]. However, SPP1 
promotes a M1-type polarization with increased expression of MCP-1 [31] while Metrnl is 
predominantly regulated by the PGC-1α4 isoform and subsequently promotes alternative activation of 
macrophages in adipose tissue in an indirect manner involving eosinophile-secreted IL-4 [32]. 
12 
Therefore, the identity of a PGC-1α- and PGC-1β-controlled myokine that promotes this anti-
inflammatory environment and possibly a M2-type macrophage polarization in skeletal muscle in a 
paracrine manner remains elusive. Nevertheless, pharmacological targeting of the immunomodulatory 
effect of the PGC-1s in muscle and thereby promotion of an anti-inflammatory environment could be a 
novel strategy for metabolic and muscle wasting diseases. 
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Figure legends 
Figure 1. Muscle PGC-1α and PGC-1β do not suppress systemic pro-inflammatory factors after 
LPS/TNFα injection in vivo A, B. PBS, LPS or TNFα were injected i.m. into the TA of MCKα (A) and 
MCKβ (B) mice and their respective WT controls. Serum levels of TNFα and IL-6 were determined 
4h post injection. Values represent the mean of at least 7 animals +SEM. ** P<0.01, * P<0.05, WT 
versus MCKα or MCKβ, respectively. 
 
Figure 2. Muscle PGC-1α and PGC-1β do not suppress acute inflammation, but reduce the expression 
of the M1 cytokine IL-12 A-F. PBS, LPS or TNFα were injected i.m. into the TA of MCKα (A, C, E) 
and MCKβ (B, D, F) mice and their respective WT controls. C, D. mRNA expression levels of PGC-1 
isoforms and different M1 cytokines in TA were measured by RT-PCR. Values represent the mean of 
at least 7 animals +SEM. ** P<0.01, * P<0.05, WT versus MCKα or MCKβ, respectively. E, F. TA 
cross sections were stained with hematoxylin and eosin (H&E) 4h post injection for histological 
analysis. Representative images are shown.  
 
Figure 3. Muscle PGC-1α and PGC-1β induce local anti-inflammatory M2 cytokines in the TA after 
LPS/TNFα injection A, B. PBS, LPS or TNFα were injected i.m. into the TA of MCKα (A) and MCKβ 
(B) mice and their respective WT controls. mRNA expression levels of different M2 cytokines in TA 
were measured by RT-PCR. Values represent the mean of at least 7 animals +SEM. ** P<0.01, * 
P<0.05, WT versus MCKα or MCKβ, respectively. 



Supplemental Table 1 RT-PCR primers 
 
Gene Forward primer Reverse primer 
CCL1 ACAGGAGGAGCCCATCTTTC CTGCCGTGTGGATACAGGAT 
CCL22 TGGAGTAGCTTCTTCACCCA TCTGGACCTCAAAATCCTGC 
F4/80+ CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
IL-1Ra AAATCTGCTGGGGACCCTAC TGAGCTGGTTGTTTCTCAGG 
IL-10 CTGGACAACATACTGCTAACCG GGGCATCACTTCTACCAGGTAA 
IL-12 GCTTCTCCCACAGGAGGTTT CTAGACAAGGGCATGCTGGT 
IL-6 CCACGGCCTTCCCTACTTC TTGGGAGTGGTATCCTCTGTGA 
MCP-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
MIP-1α TCCCAGCCAGGTGTCATTTT TTGGAGTCAGCGCAGATCTG 
PGC-1α TGATGTGAATGACTTGGATACAGACA GCTCATTGTTGTACTGGTTGGATATG 
PGC-1β GGCAGGTTCAACCCCGA CTTGCTAACATCACAGAGGATATCTTG 
TBP GGCCTCTCAGAAGCATCACTA GCCAAGCCCTGAGCATAA 
TGFβ CAACCCAGGTCCTTCCTAAA GGAGAGCCCTGGATACCAAC 
TNFα CACAAGATGCTGGGACAGTGA TCCTTGATGGTGGTGCATGA 
 
PGC-1
Exercise
Anti-inflammatory,
tissue repair and
regeneration
Inflammation
M2 M1
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tissue MF
Muscle fiber
Anti-inflammatory cytokines IL-12
?
